News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
no_data1Bitget UEX Daily | Houthi Armed Forces Join Middle East Conflict, Two Oil Futures Surge Over 3%; Analysts Predict Tesla and SpaceX May Complete Merger in 2027 (March 30, 2026)2Even a "ceasefire" does not mean "normalization," the world in 2026 will be more "stagflated" than expected3Iran Oil Waiver Releases 140 Million Barrels to Ease Price Pressure—Yet Boosts Iran’s Revenue, Heightening Risks for Market Balance
Flash
13:23
REALLOYS INC (NASDAQ: ALOY) has announced a significant personnel appointment: Joe Kasper has joined the company as Chairman of its Advisory Board.Joe Kasper has a strong background in public policy and national security, and is best known for his tenure as Chief of Staff to the U.S. Secretary of Defense. This appointment aims to leverage Kasper's professional expertise in defense and strategic planning to provide high-level guidance for the company's strategic development. His addition is expected to bring valuable insights to REALLOYS INC as it expands its operations in a complex international environment.
13:23
Metal 3D printing solutions provider Velo3D Inc announces it has secured a multi-year contract worth up to $9.8 million.This contract was awarded by the U.S. Department of Defense and is intended to provide critical support to the Defense Logistics Agency. This cooperation marks a major breakthrough in the application of Velo3D's advanced manufacturing technology in the defense sector. During the execution of the contract, the company will rely on its innovative Sapphire printing system and end-to-end solutions to provide high-precision, high-performance metal component manufacturing services for the defense logistics support system.
13:22
Anixa Biosciences announces that clinical trial results for its CAR-T therapy targeting ovarian cancer will be officially released at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer.This important development highlights the company's ongoing exploration in the innovative field of cancer immunotherapy.
News